News

Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.
Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?
CVS is set to drop Zepbound as a medicine, but will continue to carry other popular weight loss drugs instead.
Zepbound is an injectable medication approved by the U.S. Food and Drug Administration (FDA) for weight loss, and its key ingredient is tirzepatide. While Zepbound may be a powerful tool for ...
But Zepbound is only for people with obesity and sleep apnea, the society noted. Also, Zepbound can reduce the severity of sleep apnea through weight loss, but might not cure the problem.
With the addition of 12.5 mg and 15 mg vials, all approved doses of Zepbound will be available in single-dose vials for $499/month or less, regardless of insurance status, under ...
Under Lilly’s savings-card program for commercially insured people who lack coverage for Zepbound, a one-month prescription for Zepbound pens now costs a minimum of $650, up from $550 previously.
Zepbound (tirzepatide) is FDA-approved for chronic weight management in adults diagnosed with obesity or overweight who have at least one weight-related medical condition.
Zepbound may not be safe to use during pregnancy. Zepbound may also not be safe to use while breastfeeding. Zepbound can interact with birth control pills, potentially making them less effective ...
She cycled through various formulations of the blockbuster therapies semaglutide (sold under the brand names Ozempic and Wegovy) and tirzepatide (sold as Zepbound for weight loss), finding some ...
In the results, dual GLP-1/GIP agonist Zepbound (tirzepatide) outperformed GLP-1 agonist Wegovy (semaglutide) on all weight-loss endpoints at 72 weeks among patients with obesity or who were ...
All of the shifts in spending made room for Lilly’s Zepbound to re-enter the ranking at No. 8, the same spot it held in March before slipping off the list in April.